TAKE A LOOK AT WHICH REPORT YOUR PORTFOLIO'S BEEN MISSING...

Shareholders Foundation offers real-time reporting of class action exposure on a per transaction basis,
including the documents you will need for claim filing and settlement recovery.
Start Monitoring Your Investments

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Investor Investigation Concerning Potential Violations Of Securities Laws Announced

  • If you purchased shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), you have certain options and you should contact the Shareholders Foundation, Inc.

  • To have your information reviewed for options and to receive notifications about this case, please use this form. You may also send an email to mail@shareholdersfoundation.com, or call us at (858) 779-1554.

Investigation Overview

February 17, 2016 (Update) - On February 8, 2016, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced results from OPuS-2 (Oral ProphylaxiS-2), a clinical trial ofavoralstat administered three times daily as a liquid-filled soft gel formulation for the prophylactic treatment of hereditary angioedema (HAE) attacks. BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) declined to as low as ...



You must register (for free) or login to view the entire investigation.

Click here to Sign In or Register (for a free account)

@screen width:
@theme:
@breakpoints:
@layout: